Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-12-10 08:30 1529

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-11-28 13:04 1824

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-11-06 09:08 1477

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-11-06 08:30 1560

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

* This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the th...

2024-10-18 10:35 2194

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-10-07 13:14 1844

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

* XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO® has been approv...

2024-09-23 17:42 3500

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announc...

2024-08-23 12:32 3787

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approv...

2024-08-06 08:00 1905

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM)...

2024-07-05 21:18 6545

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health I...

2024-06-26 16:44 3798

Antengene To Present One Oral and Four Abstracts at ASCO 2024

* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody ...

2024-05-24 08:30 2932

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

* Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for c...

2024-04-25 20:00 2181

Antengene Presents Four Preclinical Posters at AACR 2024

SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-04-06 08:30 3700

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

* Promising clinical activities and efficacies during dose escalations for four lead global right...

2024-03-22 18:00 6302

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2024-03-20 20:30 2612

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2024-03-20 08:30 2023

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) a...

2024-03-06 08:30 2359

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List

SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2023-12-14 09:55 2060

Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will ev...

2023-12-11 08:30 1665